ARTICLE | Strategy
Back to Ipsen’s roots
Why Ipsen is revving up clinical-stage BD and adding a venture fund
July 14, 2017 8:34 PM UTC
After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But the late-stage deals came at the expense of filling the pipeline, while the research-driven strategy set in motion at that time has not borne fruit.
The company’s pipeline has a plethora of line extensions for marketed products, but just six new therapeutics and one imaging agent. The most advanced programs are in Phase II testing (see “Thinning on Top”). ...
BCIQ Company Profiles